Member Info for Professor1

@Stay.calm

Absolutely. I have had the opportunity to look at Business Combinations in my area of work for non listed group companies but there always was additional time required, usually by the legal team.

I therefore think that in this case, its probably very near completion and they want to be safe.

GLA

Business combinations are a very complex matter. Things always move due to different departments, legal etc wanting further information before signing off their bit to get it absolutely spot on otherwise can prove very costly.

GLA

NOT MUCH ADDITIONAL TIME MAY BE REQUIRED TO COMPLETE THE DEAL.

GLA

"TETE’s board of directors (the “Board”) has determined that it is in the best interests of TETE to seek an extension of the Termination Date and

have TETE shareholders approve the Extension Amendment Proposal to allow for additional time to consummate a Business Combination if needed. "

"While TETE is using its best efforts to complete a Business Combination on or before the

Termination Date, the Board believes that it is in the best interests of TETE shareholders that an extension of the Combination Period (the “Extension”) be

obtained so that, TETE will have an additional amount of time to consummate a Business Combination. "

NOTE THE WORDS:

"IF NEEDED" "TO COMPLETE ON OR BEFORE"

GLA HOLDERS

Soon

GLA

@TSSZ

It is absolutely clear you have no idea about this co and its prospects.

GLA

My view, likely around £7

GLA

In my view, GGP had very likely made an offer to WSBN on the cheap which RP declined, hence the proposed road connection to Nifty. WSBN will soon show its potential.

GLA

@roger65

I am absolutely staggered that you think that it will be Tim who will be negotiating with the big pharma lawyers.

As far as I am aware, IMM have Corporate Legal representative in the name of Broadfield Law UK LLP. They are a very large legal firm with 400 staff, 237 Solicitors and 67 Partners.

GLA

Indeed, can't understand why anyone after investing here would talk their investment down.

In my view, Avion, I am certain, like what we now have.

GLA

OTM

I refer to your post copied below:

"I’ve said before he will be in jail if he gets nothing done. There will be a number of lawsuits against him and rightly so, I have never seen anything quite like him (in those interviews)."

Can you please elaborate and enlighten us on your statement above.

GLA

@miningforgold

Thanks for posting this

GLA

@mcmickeyh

It will be more like £7 to £10 depending on various assumptions including discount factor, tax etc etc

GLA

@miningforgold

Agree, never ever seen such a disclosure in audited accounts.

To me it signals:

1) Tighter capital management by the company

2) Investor confidence and removal of uncertainty over operations

3) Clear strategic path identified for the business going forward

4) Absolute transparency

GLA

Are we going to see 100%+ increases?

When buyers want shares but there's no free float (few public shares) or sellers on the LSE, demand skyrockets, driving prices up dramatically, creating extreme illiquidity, and often leading to share suspensions or eventual buy-ins if a seller is found, highlighting a market failure where trades can't execute despite interest, a common issue in micro-caps or when major holders lock up shares.

What Happens (Mechanics):

Bids vs. Asks: Buyers place bids (offers to buy), and sellers place asks (offers to sell). If no sellers (asks) match the buyers' bids, trades don't happen, even with high interest.

Price Explosion (If Matched): Any small seller finds immense leverage, leading to massive price jumps (e.g., 100%+ in a day) as buyers compete fiercely for the few available shares.

Liquidity Freeze: The stock effectively stops trading in normal volumes because there are no shares changing hands, even if demand is high.

Market Makers' Role: Market makers usually provide liquidity, but if they can't find shares to sell or buy, they step back, worsening the situation.

Why This Occurs (Causes):

Low Free Float: A small percentage of shares (free float) are available for public trading; most are held by founders, insiders, or long-term investors.

Share Locking: Major shareholders might hold shares for strategic reasons or under lock-up agreements, restricting supply.

Thinly Traded Stocks: Small companies often have very few shares publicly available, making them prone to this.

Consequences:

Extreme Volatility: Prices swing wildly with minimal trading volume.

Difficulty Exiting: Existing shareholders struggle to sell, and new investors can't buy easily.

Potential Suspension: The exchange might halt trading if order imbalances become too severe.

Forced Buying/Selling: Buyers might offer premiums (e.g., 50-100% over market) to convince a holder to sell, or sellers might be forced to buy back shares at high prices to cover short positions (buy-ins).

In essence, it's a market imbalance where demand far outstrips available supply, making transactions nearly impossible and creating huge price distortions.

GLA

Super prospects here about to be unleashed

GLA

At last, this is the one I invested for

GLA

Indeed @Nettles

Market size referred to by Tim is huge

GLA

Roger65

You mentioned

"I agree with otm in that a much smaller deal could well happen but I’m hoping for it sooner than June. By Easter for me, and in the region of $100m - $150m in a licensing deal."

At double digit royalties of 10%, your above figures would assume annual sales of the global pharma company to be only in the range of £1B to £1.5B. Is this the level of revenues that are envisaged from the 50 indications + Diagnostics for a global pharma co?

Tim will have none of that in my view.

GLA